Clinical and functional characterisation of a recurrent KCNQ1 variant in the Belgian population.
Jervell-Lange-Nielsen
KCNQ1
LQTS
Recurrent mutation
iPSC-CMs
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
31 01 2023
31 01 2023
Historique:
received:
19
07
2022
accepted:
15
01
2023
entrez:
1
2
2023
pubmed:
2
2
2023
medline:
3
2
2023
Statut:
epublish
Résumé
The c.1124_1127delTTCA p.(Ile375Argfs*43) pathogenic variant is the most frequently identified molecular defect in the KCNQ1 gene in the cardiogenetics clinic of the Antwerp University Hospital. This variant was observed in nine families presenting with either Jervell-Lange-Nielsen syndrome or long QT syndrome (LQTS). Here, we report on the molecular, clinical and functional characterization of the KCNQ1 c.1124_1127delTTCA variant. Forty-one heterozygous variant harboring individuals demonstrated a predominantly mild clinical and electrophysiological phenotype, compared to individuals harboring other KCNQ1 pathogenic variants (5% symptomatic before 40 years of age, compared to 24% and 29% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers, respectively, 33% with QTc ≤ 440 ms compared to 10% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers). The LQTS phenotype was most comparable to that observed for the Swedish p.(Arg518*) founder mutation (7% symptomatic at any age, compared to 17% in p.(Arg518*) variant carriers, 33% with QTc ≤ 440 ms compared to 16% in p.(Arg518*) variant carriers). Surprisingly, short tandem repeat analysis did not reveal a common haplotype for all families. One KCNQ1 c.1124_1127delTTCA harboring patient was diagnosed with Brugada syndrome (BrS). The hypothesis of a LQTS/BrS overlap syndrome was supported by electrophysiological evidence for both loss-of-function and gain-of-function (acceleration of channel kinetics) in a heterologous expression system. However, BrS phenotypes were not identified in other affected individuals and allelic KCNQ1 expression testing in patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) showed nonsense mediated decay of the c.1124_1127delTTCA allele. The c.1124_1127delTTCA frameshift variant shows a high prevalence in our region, despite not being confirmed as a founder mutation. This variant leads to a mild LQTS phenotype in the heterozygous state. Despite initial evidence for a gain-of-function effect based on in vitro electrophysiological assessment in CHO cells and expression of the KCNQ1 c.1124_1127delTTCA allele in patient blood cells, additional testing in iPSC-CMs showed lack of expression of the mutant allele. This suggests haploinsufficiency as the pathogenic mechanism. Nonetheless, as inter-individual differences in allele expression in (iPSC-) cardiomyocytes have not been assessed, a modifying effect on the BrS phenotype through potassium current modulation cannot be excluded.
Sections du résumé
BACKGROUND
The c.1124_1127delTTCA p.(Ile375Argfs*43) pathogenic variant is the most frequently identified molecular defect in the KCNQ1 gene in the cardiogenetics clinic of the Antwerp University Hospital. This variant was observed in nine families presenting with either Jervell-Lange-Nielsen syndrome or long QT syndrome (LQTS). Here, we report on the molecular, clinical and functional characterization of the KCNQ1 c.1124_1127delTTCA variant.
RESULTS
Forty-one heterozygous variant harboring individuals demonstrated a predominantly mild clinical and electrophysiological phenotype, compared to individuals harboring other KCNQ1 pathogenic variants (5% symptomatic before 40 years of age, compared to 24% and 29% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers, respectively, 33% with QTc ≤ 440 ms compared to 10% in p.(Tyr111Cys) and p.(Ala341Val) variant carriers). The LQTS phenotype was most comparable to that observed for the Swedish p.(Arg518*) founder mutation (7% symptomatic at any age, compared to 17% in p.(Arg518*) variant carriers, 33% with QTc ≤ 440 ms compared to 16% in p.(Arg518*) variant carriers). Surprisingly, short tandem repeat analysis did not reveal a common haplotype for all families. One KCNQ1 c.1124_1127delTTCA harboring patient was diagnosed with Brugada syndrome (BrS). The hypothesis of a LQTS/BrS overlap syndrome was supported by electrophysiological evidence for both loss-of-function and gain-of-function (acceleration of channel kinetics) in a heterologous expression system. However, BrS phenotypes were not identified in other affected individuals and allelic KCNQ1 expression testing in patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) showed nonsense mediated decay of the c.1124_1127delTTCA allele.
CONCLUSIONS
The c.1124_1127delTTCA frameshift variant shows a high prevalence in our region, despite not being confirmed as a founder mutation. This variant leads to a mild LQTS phenotype in the heterozygous state. Despite initial evidence for a gain-of-function effect based on in vitro electrophysiological assessment in CHO cells and expression of the KCNQ1 c.1124_1127delTTCA allele in patient blood cells, additional testing in iPSC-CMs showed lack of expression of the mutant allele. This suggests haploinsufficiency as the pathogenic mechanism. Nonetheless, as inter-individual differences in allele expression in (iPSC-) cardiomyocytes have not been assessed, a modifying effect on the BrS phenotype through potassium current modulation cannot be excluded.
Identifiants
pubmed: 36721196
doi: 10.1186/s13023-023-02618-4
pii: 10.1186/s13023-023-02618-4
pmc: PMC9887867
doi:
Substances chimiques
KCNQ1 Potassium Channel
0
KCNQ1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Informations de copyright
© 2023. The Author(s).
Références
J Arrhythm. 2016 Oct;32(5):381-388
pubmed: 27761162
Heart Lung Circ. 2019 May;28(5):735-741
pubmed: 29581040
Circulation. 2007 May 15;115(19):2481-9
pubmed: 17470695
N Engl J Med. 2010 Oct 7;363(15):1397-409
pubmed: 20660394
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):868-77
pubmed: 22895603
J Mol Cell Cardiol. 2010 Jun;48(6):1096-104
pubmed: 19913547
Circulation. 2005 Oct 25;112(17):2602-10
pubmed: 16246960
Clin Pharmacol Ther. 2017 Aug;102(2):203-208
pubmed: 28718902
Heart Rhythm. 2009 Sep;6(9):1297-303
pubmed: 19716085
Nature. 1996 Nov 7;384(6604):78-80
pubmed: 8900282
J Med Genet. 2017 Jun;54(6):390-398
pubmed: 28264985
Circ Cardiovasc Genet. 2009 Dec;2(6):558-64
pubmed: 20031635
Nature. 1996 Nov 7;384(6604):80-3
pubmed: 8900283
Circ Genom Precis Med. 2018 Nov;11(11):e002345
pubmed: 30571187
J Am Coll Cardiol. 2018 Apr 17;71(15):1663-1671
pubmed: 29650123
BMC Cardiovasc Disord. 2014 Feb 19;14:22
pubmed: 24552659
PLoS One. 2011 Apr 08;6(4):e18293
pubmed: 21494607
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
N Engl J Med. 2003 May 8;348(19):1866-74
pubmed: 12736279
J Mol Diagn. 2017 May;19(3):445-459
pubmed: 28341588
Circulation. 2007 Nov 20;116(21):2366-75
pubmed: 17984373
Genet Med. 2007 Jan;9(1):23-33
pubmed: 17224687
Biol Open. 2022 Feb 15;11(2):
pubmed: 35195246
Circulation. 2009 Oct 27;120(17):1657-63
pubmed: 19822806
Heart Rhythm. 2005 May;2(5):507-17
pubmed: 15840476
J Cardiovasc Electrophysiol. 2014 May;25(5):522-530
pubmed: 24400717
Heart Rhythm. 2016 Jan;13(1):190-8
pubmed: 26334569
Stem Cell Res. 2019 Apr;36:101416
pubmed: 30878014
Circ Res. 2006 Nov 10;99(10):1076-83
pubmed: 17053194